#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

A new device in intervention therapy of heart failure with preserved ejection fraction of left ventricle


Authors: F. Málek;  M. Mates;  T. Mráz;  P. Neužil
Authors‘ workplace: Kardiocentrum, Nemocnice Na Homolce, Praha
Published in: Kardiol Rev Int Med 2015, 17(3): 202-206
Category: Cardiology Review

Overview

Chronic heart failure with preserved ejection fraction (HFpEF) is common and yet therapeutic options available to date are limited. Increased left atrial pressure is a key contributor to the symptoms in HFpEF. A novel catheter-based device has been developed, which is designed to lower left atrial pressure by creating a permanent shunt in the atrial septum. Use of this device could reduce the risk of hospitalisation for heart failure and improve the symptomatic status and quality of life in HFpEF patients with advanced symptoms.

Keywords:
heart failure with preserved ejection fraction – left atrium – catheter-based therapy – interatrial septum device


Sources

1. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population‑based study. N Engl J Med 2006; 355: 260– 269.

2. Redfield MM, Jacobsen SJ, Burnett JC Jr et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194– 202.

3. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE‑ HF Registry. J Am Coll Cardiol 2007; 50: 768– 777.

4. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251– 259.

5. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65– 75. doi: 10.1161/ CIRCULATIONAHA.111.080770.

6. McMurray J, Ostergren J, Pfeffer M et al. Clinical fea­tures and contemporary management of patients with low and preserved ejection fraction heart fail­ure: baseline characteristics of patients in the Candesartan in Heart failure‑Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261– 270.

7. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55: 526– 537. doi: 10.1016/ j.jacc.2009.06.067.

8. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456– 2467. doi: 10.1056/ NEJMoa0805450.

9. Cleland JG, Tendera M, Adamus J et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP‑ CHF) study. Eur Heart J 2006; 27: 2338– 2345.

10. Campbell RT, Jhund PS, Castagno D et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG‑ PEF, CHARM‑ Preserved, and I‑ PRESERVE? J Am Coll Cardiol 2012; 60: 2349– 2356. doi: 10.1016/ j.jacc.2012.04.064.

11. Pitt B, Pffefer MA, Assman SF et al. The TOPCAT Investigators. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014, 370: 1383– 1392. doi: 10.1056/ NEJMoa1313731.

12. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the dia­gnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Dia­gnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology – developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787– 1847. doi: 10.1093/ eurheartj/ ehs104.

13. Hradec J, Vítovec J, Špinar J. Souhrn Doporučených postupů ESC pro dia­gnostiku a léčbu srdečního selhání 2012. Cor Vasa 2013; 55: e25– e40.

14. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart fail­ure. Circulation 2007; 116: 1482– 1487.

15. Lam CS, Donal E, Kraigher‑ Krainer E et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13: 18– 28. doi: 10.1093/ eurjhf/ hfq121.

16. Andersen MJ, Ersboll M, Bro‑Jeppesen J et al. Exercise hemodynamics in patients with and without diastolic dysfunction and preserved ejection fraction after myocardial infarction. Circ Heart Fail 2012; 5: 444– 451. doi: 10.1161/ CIRCHEARTFAILURE.112.967919.

17. Maeder MT, Thompson BR, Htun N et al. Hemodynamic determinants of the abnormal cardiopulmonary exercise response in heart failure with preserved left ventricular ejection fraction. J Card Fail 2012; 18: 702– 710. doi: 10.1016/ j.cardfail.2012.06.530.

18. Holland DJ, Prasad SB, Marwick TH. Prognostic Implications of Left Ventricular Filling Pressure With Exercise. Circ Cardiovasc Imaging 2010; 3: 149– 156. doi: 10.1161/ CIRCIMAGING.109.908152.

19. Dorfs S, Zeh W, Hochholzer W et al. Pulmonary capillary wedge pressure during exercise and long‑term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 2014; 35: 3103– 3112. doi: 10.1093/ eurheartj/ ehu315.

20. Lutembacher R. De la stenose mitrale avec com­munication interauirulaier. Arch Mal Coeur 1916; 9: 237– 260.

21. Ewert P, Berger F, Nagdyman N et al. Masked left ventricular restriction in elderly patients with atrial septal defects: a contraindication for closure? Catheter Cardiovasc Interv 2001; 52: 177– 180.

22. Søndergaard L, Reddy V, Kaye D et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 2014; 16: 796– 801. doi: 10.1002/ ejhf.111.

23. Kaye D, Shah SJ, Borlaug BA et al. Effects of an interatrial shunt on rest and exercise hemodynamics: results of a computer simulation in heart fail­ure. J Card Fail 2014; 20: 212– 221. doi: 10.1016/ j.cardfail.2014.01.005.

24. Malek F, Neuzil P, Gustafsson F et al. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol 2015; 187: 227– 228. doi: 10.1016/ j.ijcard.2015.03.198.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology

Article was published in

Cardiology Review

Issue 3

2015 Issue 3

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#